Skip to main content
PepStack
Blutwerte · Marker

Immunglobulin A

Immunoglobulin A · IgA · Salivary IgA

ImmunsystemZeitabhängig
Einheit:
g/L
Abbreviation
IgA

IgA measures the concentration of immunoglobulin A antibodies in the blood or other body fluids.

Reference Ranges

Reference
0.74g/L
0.7
4
LowNormalHigh
Reference
Unit · g/L

Reference ranges may vary by laboratory and population. Age and sex-specific differences exist.

Overview

Übersicht

Immunoglobulin A (IgA) is a critical component of the immune system, primarily found in mucosal areas such as the gut, respiratory tract, and urogenital tract, as well as in saliva, tears, and breast milk. It plays a significant role in mucosal immunity by preventing the colonization of pathogens and neutralizing toxins. Clinically, IgA is important for diagnosing and monitoring autoimmune conditions such as IgA nephropathy, a common form of glomerulonephritis characterized by IgA deposition in the kidneys. Elevated IgA levels can indicate chronic infections, liver disease, or autoimmune disorders, while low levels may suggest immunodeficiency. In the context of athletic performance and biohacking, IgA is considered a marker of immune function, with implications for recovery and susceptibility to infections. Athletes often monitor IgA to optimize training loads and recovery strategies. However, IgA levels can be influenced by factors such as stress, hydration status, and recent infections, which should be considered when interpreting results. Researchers found that IgA levels can vary with circadian rhythms and may be affected by acute stress, as observed with interventions like L-Theanine, which can reduce stress-induced IgA fluctuations.

Klinische Bedeutung

Elevated IgA levels may indicate chronic infections, liver disease, or autoimmune disorders such as IgA nephropathy. Reduced IgA levels can suggest immunodeficiency or increased susceptibility to infections.

Dynamics

Trend Interpretation

Rising Values

Increasing IgA levels may suggest worsening of chronic infections or autoimmune activity. Re-test in 4-6 weeks if elevated.

Falling Values

Decreasing IgA levels could indicate improvement in underlying conditions or potential immunodeficiency.

Re-test Interval

4-6 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Chronic infections
  • Liver disease
  • Autoimmune disorders
  • IgA nephropathy
  • Inflammatory bowel disease
Cause

Low Levels

  • Immunodeficiency
  • Selective IgA deficiency
  • Chronic stress
  • Certain medications
Protocol

How to Optimize

Lever

Lifestyle

  • Manage stress through mindfulness or relaxation techniques
  • Ensure adequate sleep
  • Regular moderate exercise
Lever

Nutrition

  • Consume a balanced diet rich in fruits and vegetables
  • Include probiotics for gut health
Lever

Supplementation

  • Vitamin D
  • Zinc

Note:

Consult a healthcare provider before starting any supplementation, especially if you have underlying health conditions.

Testing Guidelines

Fasting Not Required
🕐Time-Sensitive

IgA levels can vary with circadian rhythms; consistent timing of tests is recommended.

Testing Frequency

Annually for general health monitoring, more frequently if monitoring specific conditions.

Interfering Factors

  • Recent intense exercise
  • Acute stress
  • Hydration status

Related Peptides & Hormones

Cortisol

May affect

hormone or peptide

Open Research Questions

Current research suggests that reference ranges and optimal targets for immunoglobulin A (IgA) in various diseases, such as IgA nephropathy and SARS-CoV-2 infection, remain poorly defined. Researchers have not yet established the impact of confounding factors, such as ethnicity and comorbidities, on IgA levels. Additionally, clinical questions regarding the predictive value of IgA as a biomarker for treatment response and disease progression in IgAN and viral infections remain unanswered.

23 Research Publications

1,121

Total Citations

11

Human/RCT

8.7

Avg. Influence

2025

Latest

Sort
Filter
#01

L-Theanine reduces psychological and physiological stress responses.

HumanInfluence14.0
353
This study examined the effects of L-Theanine on stress responses, finding that it significantly reduced heart rate and salivary immunoglobulin A (s-IgA) during stress tasks. Researchers observed that these effects may be linked to reduced sympathetic nervous system activation.
View on PubMed
#02

IgA Nephropathy: An Interesting Autoimmune Kidney Disease.

ReviewInfluence11.0
216
This study examined Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis, which can lead to chronic kidney disease. Researchers found that there is currently no specific biomarker to replace kidney biopsy for diagnosis, and significant variability exists in disease progression among different populations.
View on PubMed
#03

Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis.

UnknownInfluence10.0
194
Researchers identified that gut microbiota-specific IgA+ B cells can traffic to the central nervous system (CNS) in multiple sclerosis (MS). The study found a strong IgA enrichment in active MS, suggesting a role for IgA in neuroinflammation. This highlights the potential of IgA as a biomarker for MS.
View on PubMed
#04

The clinical significance of immunoglobulin A deficiency.

ReviewInfluence12.0
187
This study reviewed the clinical significance of Immunoglobulin A (IgA) deficiency, which is the most common primary immunoglobulin deficiency. Researchers found that while many individuals are asymptomatic, those with symptoms often experience severe infections and have associations with autoimmune diseases.
View on PubMed
#05

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy.

HumanInfluence2.0
52
Researchers investigated the effects of Telitacicept on biomarkers in patients with Immunoglobulin A nephropathy (IgAN). They found significant reductions in galactose-deficient IgA1 and IgA-containing immune complexes, which were associated with decreased proteinuria, indicating a potential biomarker for treatment response.
View on PubMed
#06

Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination.

Human
32
Researchers explored the presence of immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein (MOG) in patients with central nervous system demyelination. They found isolated MOG-IgA in a subgroup of patients, suggesting it may serve as a novel diagnostic biomarker. The study indicates that MOG-IgA could be relevant in understanding the pathogenesis of demyelinating diseases.
View on PubMed
#07

Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.

UnknownInfluence3.0
29
Researchers explored the role of microscopic hematuria as a potential risk factor for progression in immunoglobulin A nephropathy (IgAN). The study discussed the challenges in standardizing hematuria assessments and called for its inclusion in clinical decision-making to guide treatment strategies in IgAN.
View on PubMed
#08

IgA vasculitis following COVID-19 vaccination.

Case Report
17
Researchers reported two cases of Immunoglobulin A vasculitis following COVID-19 vaccination. They observed symptoms such as purpura and arthritis, and noted that both patients responded well to treatment with prednisolone.
View on PubMed
#09

Immunoglobulin A response to SARS-CoV-2 infection and immunity.

Review
14
This study reviewed the role of Immunoglobulin A (IgA) in response to SARS-CoV-2 infection. Researchers emphasized that IgA serves as a critical mucosal antibody and a promising biomarker for early detection and diagnosis of COVID-19.
View on PubMed
#10

Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy.

Review
9
Researchers synthesized advances in the molecular pathogenesis of Immunoglobulin A nephropathy (IgAN) and proposed a new model called the 'spiral hypothesis' to explain the disease's chronic nature. They highlighted the potential of emerging targeted therapies and the importance of biomarker-guided treatment strategies.
View on PubMed

Publication Trend

Research publications about Immunglobulin A over time

9total
2
'07
1
'18
1
'20
1
'22
3
'24
1
'25

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer